NCT00482248View on ClinicalTrials.gov

Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Asthma
Interventions
DRUG

Omalizumab

Sponsors

Lead Sponsor

Novartis

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Novartis

INDUSTRY